首页> 外文OA文献 >>High Systemic Immune-Inflammation Index Predicts Poor Survival in Patients with Human Epidermal Growth Factor Receptor-2 Positive Breast Cancer Receiving Adjuvant Trastuzumab

【2h】

>High Systemic Immune-Inflammation Index Predicts Poor Survival in Patients with Human Epidermal Growth Factor Receptor-2 Positive Breast Cancer Receiving Adjuvant Trastuzumab

机译：>高全身免疫炎症指数预测人体表皮生长因子受体-2阳性乳腺癌患者的存活率差，接受佐剂曲妥珠单抗

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Li Jiang; Jianjiang Fang; Jinhua Ding;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. High Systemic Immune-Inflammation Index Predicts Poor Survival in Patients with Human Epidermal Growth Factor Receptor-2 Positive Breast Cancer Receiving Adjuvant Trastuzumab [J] . Li Jiang, Jianjiang Fang, Jinhua Ding Cancer Management and Research . 2020,第4期

机译：高全身免疫炎症指数预测人表皮生长因子受体-2阳性乳腺癌接受佐剂曲据的患者存活率不佳
2. Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: Results from North Central Cancer Treatment Group adjuvant trial N9831 [J] . Moreno-AspitiaA., HillmanD.W., DyarS.H., Cancer: A Journal of the American Cancer Society . 2013,第15期

机译：接受或不接受曲妥珠单抗化疗的HER2阳性乳腺癌患者中可溶性人类表皮生长因子受体2（HER2）的水平：北中部癌症治疗组辅助试验N9831的结果
3. Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy [J] . Zardavas Dimitrios, Suter Thomas M., Van Veldhuisen Dirk J., Journal of Clinical Oncology . 2017,第8期

机译：脑钠尿肽的肌钙蛋白I和T和N-末端前骨酮类对早期人体表皮生长因子受体2阳性乳腺癌患者心脏安全性的作用，接受曲妥珠单抗：赫赛汀佐剂研究心脏标志物归档
4. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019

机译：HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关：回顾性和多中心研究
5. Indirect Costs Associated with Human Epidermal Growth Factor Receptor Positive (HER2+) Metastatic Breast Cancer [D] . Wright, Phoebe. 2020

机译：与人表皮生长因子受体阳性（HER2 +）转移性乳腺癌相关的间接成本
6. High Systemic Immune-Inflammation Index Predicts Poor Survival in Patients with Human Epidermal Growth Factor Receptor-2 Positive Breast Cancer Receiving Adjuvant Trastuzumab [O] . Li Jiang, Jianjiang Fang, Jinhua Ding 2020

机译：高系统性免疫炎症指数预示接受曲妥珠单抗辅助治疗的人表皮生长因子受体2阳性乳腺癌患者的生存率较低
7. Factors affecting disease-free survival in patients with human epidermal growth factor receptor 2-positive breast cancer who receive adjuvant trastuzumab [O] . SEYDA GÜNDÜZ, SEMA SEZGIN GÖKSU, DENIZ ARSLAN, 2015

机译：影响人体表皮生长因子受体2阳性乳腺癌患者患者免疫生存的因素，接受佐剂曲妥珠单抗

>High Systemic Immune-Inflammation Index Predicts Poor Survival in Patients with Human Epidermal Growth Factor Receptor-2 Positive Breast Cancer Receiving Adjuvant Trastuzumab

著录项

引文网络

相似文献

相关主题

期刊订阅